Treating Blood Pressure and Cholesterol in People at Risk for Dementia
Tests blood pressure and cholesterol medicines in 10 people at risk for dementia.
Plain-language title generated from the registry record
Registry title: Vascular Intervention Strategies Trial for Alzheimer's
Key facts
- Where
- Los Angeles, United StatesSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 75 years old?
Source: NCT07447206, who can take part
Where in United States
- Clinical Sciences Building (CSC)Los Angeles, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Southern California
- Trial code
- NCT07447206
- Record updated
- 4 May 2026
- Original description
The proposed pharmacist-led study is a feasibility pilot trial for the management of vascular risk factors of hypertension and hypercholesterolemia in 10 APOE ε4 carriers, 50-75, at-risk for dementia. All participants will receive angiotensin receptor blockers (ARBs) for high blood pressure, and hydrophilic statins (or a non-statin alternative) for high cholesterol over a six-month period.Read full original descriptionShow less
Vascular Intervention Strategies Trial for Alzheimer's (VISTA)
The proposed pharmacist-led study is a feasibility pilot trial for the management of vascular risk factors of hypertension and hypercholesterolemia in 10 APOE ε4 carriers, 50-75, at-risk for dementia. All participants will receive angiotensin receptor blockers (ARBs) for high blood pressure, and hydrophilic statins (or a non-statin alternative) for high cholesterol over a six-month period.
Inclusion: APOE ε4 carrier (homozygote or heterozygote); LDL-C of 100-250 mg/dL; Systolic blood Pressure (SBP) 130-180 mm Hg; Age 50-75 years; Fluency in English; No dementia based on medical record review; Male or post-menopausal female.
Exclusion: Contraindications to blood pressure and cholesterol lowering medications; Receiving palliative or hospice care; Receiving chronic opioid therapy; Organ transplant; Concurrent participation in another clinical trial; Use of medications prescribed for dementia (e.g., aducanumab, donanemab, lecanemab, donepezil, galantamine, rivastigmine, memantine); Evidence of dementia based on medical record review; Bipolar illness or schizophrenia; Drug or alcohol disorder; Any significant neurological disease (e.g., Parkinson's disease, amyotrophic lateral sclerosis, or multiple sclerosis); History of stroke, symptomatic HF or left ventricular ejection fraction < 35%; ESRD or eGFR < 20 ml/min /1.73m2; One minute standing SBP < 110 mm Hg; Arm circumference prevents from accurate BP measurement with use of available devices; Lost weight of > 10% unintendedly (within the past 6 months),; Living in a skilled nursing or rehabilitation facility; Severe loss of visual, hearing or communication ability; Does not consent to be contacted or to have their medical record reviewed for research purposes.